Arrowhead Pharmaceuticals, Inc. (ARWR) stock rallied over 8.52% intraday to trade at $34.26 a share on NASDAQ. The stock opened with a gain of 14.97% at $31.75 and touched an intraday high of $34.3, rising 8.52% against the last close of $31.57. The stock went to a low of $31.68 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue144.42 Million
5Y Sales Change287.50%
Fiscal Year Ends2021-09-29
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock price is $34.26 as of the last check on Thursday, June 23. During the trading session, ARWR stock reached the peak price of $34.3 while $31.68 was the lowest point it dropped to.
The NASDAQ listed ARWR is part of Biotechnology industry that operates in the broader Health Care sector. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Dr. Vincent Anzalone
VP of Investor Relations
Dr. Christopher R. Anzalone Ph.D.
CEO, Pres & Director
Mr. Kenneth A. Myszkowski
Chief Financial Officer
Mr. Patrick O'Brien
Chief Compliance Officer, Gen. Counsel & Corp. Sec.
ARWR stock traded closed the last session at $34.26, which is $2.69 or 8.52% lower than its previous close of $31.57. ARWR's current trading price is 27.79% lower than its 52-week high of $93.66 where as its distance from 52-week low of 26.81% is -63.42%.
Number of ARWR employees currently stands at -. ARWR operates from 177 East Colorado Boulevard, Suite 700, Pasadena, CA 91105, United States.
Official Webiste of $ARWR is: https://arrowheadpharma.com
ARWR stock volume for the day was 907,755 shares while in the previous session number of ARWR shares traded was 909,700 . The average number of ARWR shares traded daily for last 3 months was 840.87 Thousands.
The percentage change in ARWR stock occurred in the recent session was 8.52% while the dollar amount for the price change in ARWR stock was $2.69.
In the recent session, the day high for ARWR stock was $34.3 while the low for ARWR stock touched on the day was $31.68.
The market value of ARWR currently stands at 3.46 Billion with its latest stock price at $34.26 and 105.55 Million of its shares outstanding.